76 related articles for article (PubMed ID: 23397357)
1. Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.
Park I; Cho YM; Lee JL; Ahn JH; Lee DH; Song C; Hong JH; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2013 May; 139(5):817-27. PubMed ID: 23397357
[TBL] [Abstract][Full Text] [Related]
2. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract][Full Text] [Related]
5. Metastatic sarcomatoid carcinoma to bone.
Sabharwal S; LiBrizzi CL; Wangsiricharoen S; Gross JM; Strike SA; Levin AS; Morris CD
J Surg Oncol; 2023 Dec; 128(8):1446-1452. PubMed ID: 37650828
[TBL] [Abstract][Full Text] [Related]
6. Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors.
Hanif A; Pandey M; Khan S; Attwood K; George S
Oncoimmunology; 2019; 8(8):1606639. PubMed ID: 31413914
[No Abstract] [Full Text] [Related]
7. Nonfamilial Bilateral Synchronous Renal Cell Carcinoma with Discordant Histology with Eventual Complete Response to Dual Immunotherapy.
Robertson IJ; Grigsby SM; Mattingly JC; Park DK
Case Rep Oncol; 2023; 16(1):1378-1383. PubMed ID: 37965647
[TBL] [Abstract][Full Text] [Related]
8. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.
Randall JM; Millard F; Kurzrock R
Cancer Metastasis Rev; 2014 Dec; 33(4):1109-24. PubMed ID: 25365943
[TBL] [Abstract][Full Text] [Related]
9. Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.
Kornakiewicz A; Solarek W; Bielecka ZF; Lian F; Szczylik C; Czarnecka AM
Curr Signal Transduct Ther; 2014 Dec; 8(3):210-218. PubMed ID: 25152703
[TBL] [Abstract][Full Text] [Related]
10. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Kroeger N; Choueiri TK; Lee JL; Bjarnason GA; Knox JJ; MacKenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Tan MH; Bamias A; Kollmannsberger CK; North SA; Rini BI; Heng DY
Eur Urol; 2014 Jun; 65(6):1086-92. PubMed ID: 23916693
[TBL] [Abstract][Full Text] [Related]
11. [A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].
Ikehata Y; Takahashi S; Kitamura H; Masumori N; Tsukamoto T
Hinyokika Kiyo; 2013 Jun; 59(6):369-72. PubMed ID: 23827870
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the sarcomatoid component in bladder cancer: A propensity score matching study.
Liu S; Yao Y; Wang ZK; Sun LJ; Zhang GM
Oncol Lett; 2023 Mar; 25(3):103. PubMed ID: 36817055
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis.
Shan L; Shao X; Gu L; Wu M; Lin P; Yu Z; Chen Q; Zhu D
Front Surg; 2022; 9():922150. PubMed ID: 36338616
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma: Associations between tumor imaging features and epidemiological risk factors.
Hötker AM; Karlo CA; Di Paolo PL; Zheng J; Moskowitz CS; Russo P; Hricak H; Akin O
Eur J Radiol; 2020 Aug; 129():109096. PubMed ID: 32559590
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
Park I; Lee HJ; Bae WK; Yoon S; Lee JL
Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
[TBL] [Abstract][Full Text] [Related]
18. [Pt(
Antonaci G; Cossa LG; Muscella A; Vetrugno C; De Pascali SA; Fanizzi FP; Marsigliante S
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30845773
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.
Maiti A; Nemati-Shafaee M; Msaouel P; Pagliaro LC; Jonasch E; Tannir NM; Shah AY
Clin Genitourin Cancer; 2017 Aug; ():. PubMed ID: 28870517
[TBL] [Abstract][Full Text] [Related]
20. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.
Thomas AZ; Adibi M; Slack RS; Borregales LD; Merrill MM; Tamboli P; Sircar K; Jonasch E; Tannir NM; Matin SF; Wood CG; Karam JA
J Urol; 2016 Sep; 196(3):678-84. PubMed ID: 27036304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
